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Purpose of review
The epidermal growth factor receptor is a cell membrane
receptor that plays a key role in cancer development and
progression. Ligand-activated epidermal growth factor
receptor-dependent signaling is involved in cell proliferation,
apoptosis, angiogenesis, invasion, and metastasis. Targeting
the epidermal growth factor receptor represents a promising
molecular approach in cancer treatment. Several antiepidermal
growth factor receptor agents are in clinical development. This
review focuses on the available clinical data on epidermal
growth factor receptor-targeting drugs in the treatment of
nonsmall cell lung cancer.
Recent findings
Three drugs are currently in phase 2 and phase 3 development
as single agents or in combination with other anticancer
therapies in nonsmall cell lung cancer patients: cetuximab
(Erbitux), a chimeric human–mouse monoclonal IgG1 antibody
that blocks ligand binding and functional epidermal growth
factor receptor activation; and erlotinib (Tarceva) and gefitinib
(Iressa), two orally bioavailable, small-molecule epidermal
growth factor receptor inhibitors of tyrosine kinase enzymatic
activity that prevent epidermal growth factor receptor
autophosphorylation and activation. Single-agent gefitinib
treatment has determined a 10 to 20% response rate and a 30
to 50% symptom improvement in previously treated,
chemotherapy-refractory advanced nonsmall cell lung cancer
patients. Gefitinib has been the first epidermal growth factor
receptor-targeting agent to be registered as an anticancer
drug in several countries, including Japan, Australia, and the
United States, for the third-line treatment of chemoresistant
nonsmall cell lung cancer patients.
Summary
Antiepidermal growth factor receptor has shown promising
antitumor activity in nonsmall cell lung cancer patients with a
mild toxicity profile. However, a series of important clinical
issues such as selection of potentially responsive patients and
optimal combination with conventional anticancer treatments
needs to be addressed to use these drugs better in lung
cancer.
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Introduction
Epidermal growth factor (EGF) belongs to a family of
related peptides (EGF-like growth factors) that includes
transforming growth factor-, amphiregulin, heparin-
binding EGF, epiregulin, heregulins, neuregulins (1, 2,
3, and 4), and betacellulin [1]. EGF-like growth factors
bind to and activate one or more closely related recep-
tors: the EGF receptor (EGFR, or ErbB-1/HER1),
ErbB-2/neu/HER2, ErbB-3/HER3, and ErbB-4/HER4
[1,2]. The EGFR is a 170-kDa transmembrane glycopro-
tein that consists of an extracellular domain, a short trans-
membrane domain, and an intracellular region contain-
ing tyrosine kinase activity. The other three family
members have a similar structure with a high degree of
homology in the tyrosine kinase domain. The extracel-
lular domains confer different specificity and selectivity
to different EGF-like growth factors and are less con-
served among the four receptors. No ligand is known for
ErbB-2. Receptors exist as inactive monomers [1,2].
Ligand binding causes homodimerization or hetero-
dimerization between the EGFR and another member of
the EGFR family, and subsequent autophosphorylation
of the intracellular domains, which initiates a cascade
of intracellular signals that directly or indirectly control
cell proliferation, angiogenesis, invasion, and metas-
tasis [2,3].
Activation of the transforming growth factor-–EGFR
autocrine growth pathway is a common mechanism for
autonomous nonsmall cell lung cancer (NSCLC) growth
[4]. This is generally the result of EGFR overexpression
without gene amplification and/or the result of increased
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concentration of ligands, such as transforming growth
factor- and amphiregulin [4]. EGFR gene amplification
is observed only in approximately 10% of NSCLCs [5].
Enhanced EGFR expression is observed in 40 to 80% of
NSCLC patients [5,6]. This is accompanied by the ex-
pression of one or more other EGFR family members
and of different ligands with a high degree of heteroge-
neity in both positivity and the levels of expression of
these proteins [6]. Although some reports have sug-
gested a correlation between EGFR overexpression and
worse survival [7], there is no definitive evidence of
a prognostic role of EGFR family members in
NSCLC [4–6].
Epidermal growth factor receptor as a
target for cancer therapy
Two types of anti-EGFR-targeting agents have reached
advanced clinical development: monoclonal antibodies
(MAbs) and small-molecule inhibitors of EGFR tyrosine
kinase enzymatic activity (Table 1) [8,9••,10••]. MAbs
against the extracellular domain of the EGFR block li-
gand binding and receptor activation. Tyrosine kinase
inhibitors (TKIs) prevent the autophosphorylation of the
EGFR intracellular tyrosine kinase domain. These mol-
ecules are generally competitors of ATP for binding to
the intracellular catalytic domain. Although MAbs are
highly specific for EGFR binding, TKIs may be less
selective and may block other members of the EGFR
family. In fact, based on the mechanism of action, small-
molecule EGFR TKIs can be distinguished as reversible
or irreversible TKIs and as selective for the EGFR
or active also against other members of the family
(Table 1).
Although the mechanism of action and the biologic ef-
fects of MAbs and small-molecule TKIs have differ-
ences, such as route of administration and biodistribu-
tion, induction of EGFR downregulation, potential
activation of immune functions that could be clinically
relevant [11•,12•], the antitumor effects of EGFR inhi-
bition in human cancer models are (1) inhibition of can-
cer cell proliferation with G0–G1 cell cycle arrest and, in
some cases, induction of apoptosis; (2) antiangiogenesis
through inhibition of angiogenic growth factor produc-
tion; (3) inhibition of invasion and metastasis; and (4)
potentiation of antitumor activity of cytotoxic drugs and
of radiotherapy [8,9••,10••].
Clinical studies with epidermal growth
factor receptor inhibitors in nonsmall cell
lung cancer
Cetuximab (Erbitux), a chimeric human–mouse anti-
EGFR MAb, and erlotinib (Tarcev) and gefitinib
(Iressa), two orally available, reversible, and selective
EGFR-TKIs, are the most advanced EGFR-targeted
drugs in NSCLC treatment and are discussed in detail in
this review.
Gefitinib
Gefitinib is a low-molecular weight (447 Da), synthetic
anilinoquinazoline derivative. Gefitinib is an orally ac-
tive, selective, and reversible inhibitor of EGFR tyrosine
kinase [13–15]. The initial five phase 1 trials of gefitinib
monotherapy that were conducted in approximately 250
heavily pretreated advanced cancer patients have shown
in 99 NSCLC patients a promising antitumor activity,
with partial responses lasting from 1 to 16 months in
eight patients and regression of nonmeasurable but
evaluable disease in two patients [16••,17••,18,19]. In
addition, approximately one third of patients have had
long-lasting stable disease for 3 months or more. Inter-
estingly, in those patients with tumor response and dis-
ease stabilization, a significant improvement in quality of
life and disease-related symptoms as measured by the
Lung Cancer Subscale of the Functional Assessment of
Cancer Therapy questionnaires was observed [20•]. Ge-
fitinib monotherapy was well tolerated. The most fre-
quently reported adverse events were diarrhea and ac-
nelike skin rash. These side effects were reversible.
Grade 3 diarrhea was dose limiting at the 700- to 1000-
mg dose level. Based on these results, two large phase 2
trials of gefitinib monotherapy in advanced NSCLC pa-








Cetuximab (Erbitux) Human–mouse chimeric MAb Selective for EGFR Phase III
EMD 72000 Humanized MAb Selective for EGFR Phase I
ABX-EGF Fully human MAb Selective for EGFR Phase I
hR3 Humanized MAb Selective for EGFR Phase I
Gefitinib (Iressa) Reversible TKI Selective for EGFR Phase III; as of November 2003,
registered in 10 countries worldwide,
including the United States, as
third-line therapy in NSCLC
Erlotinib (Tarceva) Reversible TKI Selective for EGFR Phase III
CI-1033 Irreversible TKI Pan-ErbB inhibitor Phase I
PKI-166 Reversible TKI EGFR/ErbB-2 dual inhibitor Phase I
GW2016 Reversible TKI EGFR/ErbB-2 dual inhibitor Phase I
EKB-569 Irreversible TKI EGFR/ErbB-2 dual inhibitor Phase I
EGFR, epidermal growth factor receptor; MAb, monoclonal antibody; NSCLC, nonsmall cell lung cancer; TKI, tyrosine kinase inhibitor.
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tients that have failed one or more chemotherapy lines
have been conducted. In a multicenter, European and
Japanese randomized, phase 2 trial of gefitinib as second-
or third-line single-agent therapy (IDEAL 1, or Iressa
Dose Evaluation in Advanced Lung Cancer), 210 ad-
vanced NSCLC patients who were not selected based on
EGFR expression received either 250 mg or 500 mg oral
daily treatment [21••]. An overall response rate of 18.4%
and 19% was observed in the 250-mg and 500-mg gefi-
tinib groups respectively. Stable disease was obtained in
36% and 32% patients respectively. Symptom improve-
ment rates were 40.3% and 37%, median progression-
free survival times were 2.7 months and 2.8 months, and
median overall survival times were 7.6 months and 8.0
months respectively. Gefitinib at the 250-mg daily dose
was equally active compared with 500 mg. However, the
tolerability was significantly better with the 250-mg daily
dose. A parallel phase 2, randomized study was con-
ducted in the United States (IDEAL 2) in 216 unse-
lected, symptomatic, advanced NSCLC patients who
were resistant to at least two previous chemotherapy
regimens, one containing a platinum derivative and one
containing docetaxel [22••]. NSCLC symptoms, as mea-
sured by a 2-point or greater increase in the Functional
Assessment of Cancer Therapy–Lung Cancer Subscale
score, improved in 43% of patients receiving 250 mg
gefitinib and in 35% of patients receiving 500 mg. These
effects were rapidly occurring in most patients (ie, within
3 weeks in 75% of responding patients). Partial responses
were detected in 12% and in 9% of patients treated with
gefitinib 250 mg and 500 mg respectively. Symptoms
improved in 96% of patients with partial responses. One-
year overall survival was 25%. Also in this study, the
higher dose of gefitinib was associated with worse side
effects, such as acnelike skin rash and diarrhea. On the
basis of these clinical trials, gefitinib has been licensed
for platinum and docetaxel chemorefractory advanced
NSCLC patients as third-line treatment in 10 countries,
including Japan, Australia, and the United States [23].
Therefore, gefitinib represents the first approved anti-
EGFR-targeting drug. Single-agent gefitinib antitumor
activity has also been confirmed by a large, international,
extended access program that has been conducted with
gefitinib 250 mg in advanced NSCLC patients who pro-
gressed after standard chemotherapy and/or radiation
therapy [24,25]. In these series, objective responses have
been observed in 10 to 15% of patients. Moreover, gefi-
tinib clinical activity has been reported in NSCLC el-
derly and/or poor performance status patients as well
[26•,27–29]. Gefitinib monotherapy has also shown an-
ticancer activity against brain metastasis in advanced
NSCLC patients [30•,31•]. Emerging clinical data sup-
port the hypothesis that gefitinib may be significantly
more active in certain NSCLC histotypes such as in ad-
enocarcinomas and in bronchioloalveolar carcinomas and
in women with no smoking history [32•–34•]. The role
of gefitinib in combination with chemotherapy has also
been assessed in advanced NSCLC. A pilot study has
shown that treatment with gefitinib (250 mg or 500 mg
daily dose) in combination with carboplatin–paclitaxel
appeared feasible and well tolerated in previously un-
treated patients with advanced stage IIIB to IV NSCLC
[35]. Pharmacokinetic data demonstrated that coadmin-
istration of gefitinib does not affect the clearance of ei-
ther carboplatin or paclitaxel. Of 24 patients, five had
partial responses (median duration of response, 5
months) and 11 patients obtained disease stabilization.
The median survival for the 24 patients was 8 months.
One-year and 2-year survival rates were 39% and 22%
respectively. The combination of another platinum-
based chemotherapy regimen (cisplatin–gemcitabine)
with oral gefitinib (250-mg or 500-mg daily dose) was
evaluated in 18 advanced NSCLC patients as first-line
treatment (Giaccone et al., Abstract presented at the
AACR-NCI-EORTC International Conference in Mo-
lecular Targets and Cancer Therapeutics, 2001). The
combination was tolerable, with no increase in chemo-
therapy-related toxicity and no interference with the
pharmacokinetics of these drugs. The combination of
gefitinib with docetaxel as second-line treatment is also
under evaluation in advanced NSCLC patients [36,37].
Preliminary results of these studies suggest that both
250- and 500-mg daily doses can be combined with stan-
dard-dose docetaxel (75 mg/m2 every 3 weeks). Two
large (1093 and 1037 patients in each trial respectively),
randomized, multicenter, double-blind, three-arm, pla-
cebo-controlled phase 3 trials of gefitinib (250 mg or 500
mg daily) in combination with cytotoxic agents (cisplat-
in–gemcitabine, Iressa Non-Small-Cell-Lung Cancer
Trial Assessing Combination Treatment [INTACT 1]
trial, or carboplatin–paclitaxel INTACT 2 trial) as first-
line treatment in stages IIIB to IV NSCLC patients were
conducted [38•,39•]. No patient selection based on
EGFR expression in cancer cells was done. No differ-
ence in overall survival, as the primary end point of these
two parallel studies, has been reported. Different expla-
nations for the lack of efficacy of gefitinib plus standard
doublet cytotoxic therapy have been proposed [40,41••].
Chemotherapy and gefitinib could target the same can-
cer cell population and, therefore, response to chemo-
therapy masks the response to the EGFR inhibitor. Che-
motherapy may directly or indirectly affect EGFR
function and/or expression, and thus may reduce or ab-
rogate the antitumor activity of gefitinib. It seems more
conceivable that because of the high molecular and
clonal heterogeneity of NSCLC cells, only a subset of
EGFR-positive NSCLC patients have tumors that are
significantly dependent on the EGFR pathway and who,
therefore, could obtain a clinical benefit by an anti-
EGFR drug [41••]. Interstitial lung disease (ILD) was
first reported in Japanese advanced NSCLC patients re-
ceiving gefitinib and in those who were pretreated with
chemotherapy and/or radiotherapy [42•]. ILD has been
observed in 291 of 17,500 Japanese patients (1.7%)
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treated with gefitinib [42•]. However, ILD has been ob-
served in only 0.3% of 56,000 NSCLC patients who re-
ceived gefitinib in the United States, Europe, and Aus-
tralia as part of an expanded access program [43•]. No
differences in any type of pulmonary adverse events
have been observed in the double-blind, placebo-
controlled, randomized INTACT 1 and 2 trials (0.9% in
the placebo group compared with 1.1% in the 250-
mg/day and the 500-mg/day gefitinib groups) [38•,39•].
Notably, ILD has been observed in NSCLC patients
receiving standard cytotoxic treatments (1 to 5% inci-
dence with chemotherapy or with radiotherapy) [43•]. A
series of phase 3 trials is currently evaluating the role of
gefitinib as adjuvant treatment in radically resected
NSCLC patients, the possibility of using gefitinib as
maintenance therapy after first-line chemotherapy in ad-
vanced NSCLC patients, and the antitumor activity of
gefitinib compared with docetaxel in the second-line
treatment of advanced disease.
Erlotinib
Erlotinib is a low-molecular weight, orally bioavailable,
quinazoline derivative that selectively and reversibly in-
hibits the tyrosine kinase activity of EGFR [44]. Phase 1
studies in patients with advanced solid tumors have
shown a tolerability profile similar to gefitinib. Major
toxicities were acnelike skin rash and diarrhea, which
was the dose-limiting toxicity at 200 mg daily. The rec-
ommended dose for continuous treatment was 150
mg/day [44]. Erlotinib is currently in phase 2 to phase 3
development in advanced NSCLC. Preliminary evi-
dence of antitumor activity of erlotinib in patients with
advanced NSCLC who failed a platinum-based therapy
was recently reported [45]. In this phase 2 study, a com-
plete response was observed in 1 of 57 patients, and
partial responses were obtained in six patients. Stable
disease was detected in an additional 17 patients. The
median survival for these patients was 259 days, with a
1-year survival of 48%. A retrospective analysis of acne-
like rash occurrence in this phase 2 study has suggested
that rash severity (grade 2 or more) compared with no
skin lesions is predictive of increased survival (no rash,
1.5 months median survival; grade 1 toxicity, 8.5 months
median survival; grade 2 to 3 toxicity, 19.6 months me-
dian survival) [46••]. Based on these observations and on
the hypothesis that skin rash may be a surrogate for clini-
cal activity, a trial has recently been initiated in chemo-
therapy refractory advanced NSCLC patients to evaluate
the feasibility of erlotinib dose escalation to induce tol-
erable rash without other toxicities. Interestingly, no cor-
relation between the degree of skin toxicity and outcome
has been observed so far with gefitinib clinical trials. A
series of phase 2 and phase 3 studies of erlotinib as a
single agent or in combination with various chemo-
therapy regimens is ongoing in NSCLC [47]. In this re-
spect, erlotinib treatment as a single agent is also under
evaluation in the second- or third-line treatment of ad-
vanced NSCLC patients in two randomized phase 3
clinical trials in comparison with docetaxel or with best
supportive care respectively. Similar to the INTACT tri-
als, two large (approximately 1000 patients in each
study), multicenter, randomized, phase III studies of
first-line carboplatin–paclitaxel or cisplatin–gemcitabine
with erlotinib in stage IIIB to IV NSCLC patients have
been performed (47). On October 1, 2003, a press release
from the industries (Genentech, San Francisco, CA;
Roche, Basel, Switzerland; and OSI Pharmaceuticals,
Boulder, CO) that are producing erlotinib stated that
both studies, similar to the INTACT studies with gefi-
tinib, failed to show any difference in overall survival
between the standard and the erlotinib treatment.
Cetuximab
Cetuximab is a chimeric human–mouse IgG1 anti-
EGFR-blocking MAb. It was the first anti-EGFR-
targeted agent to start clinical evaluation in cancer pa-
tients [48]. In the phase 1 studies the most frequent
cetuximab-related adverse events were skin toxicities,
fever and chills, asthenia, transient transaminase eleva-
tions, and nausea [49]. Skin toxicities were reversible
flushing, acnelike rashes, and folliculitis. The maximum
tolerated dose was not reached. Cetuximab had nonlin-
ear pharmacokinetics. Based on the doses for complete
saturation of antibody clearance, the recommended load-
ing dose and the subsequent weekly maintenance doses
for phase 2 studies were 400 mg/m2 and 250 mg/m2 re-
spectively. The combination of cetuximab with various
two-drug chemotherapy regimens has been evaluated as
first-line treatment in EGFR-positive advanced NSCLC
patients. In a phase 1/2 trial of cetuximab plus carboplat-
in–gemcitabine chemotherapy, 10 partial responses
(28.6%) and 11 stable diseases (60%) in 35 patients were
observed [50]. The median time to progression and the
median overall survival were 165 days and 310 days re-
spectively. The combination of carboplatin–paclitaxel
plus cetuximab was evaluated in 31 patients as first-line
treatment in EGFR-positive advanced NSCLC [51].
Partial responses were observed in nine patients (29%)
and disease stabilization was obtained in the other 11
patients (35.5%), with a median time to progression of
4.5 months and a median overall survival of 15.7 months.
A phase 2 trial of cetuximab in combination with doce-
taxel as second-line treatment in chemotherapy
refractory/resistant EGFR-positive advanced NSCLC
has recently been reported [52]. One complete response
and 11 partial responses (overall response rate, 22.2%)
were observed in the 54 treated patients. The other 18
patients (33.3%) had stable disease. The median overall
survival was 7.5 months. The initial results of a random-
ized, phase 2 study (LUCAS, or Lung Cancer Cetuximab
Combination Study) comparing as first-line therapy cis-
platin–vinorelbine with the same combination plus ce-
tuximab in EGFR-positive stage IIIB to IV NSCLC pa-
tients have been presented. A higher response rate with
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no increase in chemotherapy toxicity was observed in the
chemotherapy plus cetuximab group compared with the
chemotherapy-alone group: one complete response and
15 partial responses out of 30 treated patients (53.3%
response rate) versus 10 partial responses in 31 treated
patients (32.2% response rate) [54••]. However, com-
plete data from this study and phase 3 trials are necessary
to define whether cetuximab significantly improves the
activity and the efficacy of standard chemotherapy in
NSCLC.
Conclusion
Both anti-EGFR MAbs and small-molecule TKIs have
shown an excellent toxicity profile with mild and revers-
ible side effects in NSCLC patients. However, a series of
clinically important issues on the use of EGFR-targeted
therapies in NSCLC is emerging [54••]. First, the im-
portance of the measurement of the levels of expression
of EGFR within the tumor to select cancer patients for
treatment with these drugs is not yet clear. Although
EGFR expression is found in most NSCLCs, responses
are observed only in a subgroup of patients. There is no
evidence of a relation between EGFR overexpression
and likelihood to respond to anti-EGFR drugs. More-
over, it seems that adenocarcinomas and bronchioloal-
veolar carcinomas are more sensitive than squamous cell
carcinomas. Furthermore, it could be necessary for the
response to EGFR inhibitors the expression of the other
three EGFR-related receptors and of the EGFR ligands
such as transforming growth factor- and amphiregulin.
Finally, the intracellular signal transduction pathways
that act downstream to EGFR could influence the re-
sponse to anti-EGFR agents. In this respect, cancer cells
may escape from growth inhibition by using alternative
growth pathways or by constitutive activation of down-
stream signaling effectors [54••]. In summary, the imple-
mentation of translational, research-oriented clinical tri-
als with EGFR inhibitors in NSCLC is needed to
establish fully their role in NSCLC management. The
major aims of these studies should be the identification
of clinically relevant molecular markers of potential sen-
sitivity or resistance to therapy, and the identification of
pharmacologic and mechanistic interactions of anti-
EGFR agents and chemotherapy or radiotherapy for the
more appropriate integration of these drugs with conven-
tional treatment.
References and recommended reading
Papers of particular interest, published within the annual period of review,
have been highlighted as:
• Of special interest
•• Of outstanding interest
1 Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev
Mol Cell Biol 2001, 2:127–137.
2 Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 2000,
103:211–215.
3 Woodburn JR: The epidermal growth factor receptor and its inhibition in can-
cer therapy. Pharmacol Ther 1999, 82:241–250.
4 Salomon DS, Brandt R, Ciardiello F, et al.: Epidermal growth factor-related
peptides and their receptors in human malignancies. Crit Rev Oncol Haema-
tol 1995, 19:183–232.
5 Hirsh F, Varella–Garcia M, Bunn PA, et al.: Epidermal growth factor receptor
in non-small-cell lung carcinomas: correlation between gene copy number
and protein expression and impact on prognosis. J Clin Oncol 2003,
21:3798–3807.
6 Fontanini G, De Laurentiis M, Vignati S, et al.: Evaluation of epidermal growth
factor-related growth factors and receptors and of neoaniogenesis in com-
pletely resected stage I–IIIA non-small-cell lung cancer: amphiregulin and mi-
crovessel count are independent prognostic indicators of survival. Clin Can-
cer Res 1998, 4:241–249.
7 Brabender J, Danenberg KD, Metzger R, et al.: Epidermal growth factor re-
ceptor and HER2-neu mRNA expression in non-small cell lung cancer is cor-
related with survival. Clin Cancer Res 2001, 7:1850–1855.
8 Ciardiello F, Tortora G: A novel approach in the treatment of cancer: targeting
the epidermal growth factor receptor. Clin Cancer Res 2001, 7:2958–2970.
••
9 Grunwald V, Hidalgo M: Developing inhibitors of the epidermal growth factor
receptor for cancer treatment. J Natl Cancer Inst 2003, 95:851–867.
This is an updated review of EGFR inhibitors in cancer treatment.
••
10 Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antago-
nists in the biology and treatment of cancer. J Clin Oncol 2003, 21:2787–
2799.
This is an updated review of EGFR inhibitors in cancer treatment.
•
11 Baselga J: Targeting EGFR with MAbs versus TKIs: different mechanisms,
similar endpoints. Signal 2003, 4:4–6.
This paper describes the potential biologic, pharmacologic, and therapeutic differ-
ences among different classes of EGFR inhibitors.
•
12 Normanno N, Maiello MR, De Luca A: Epidermal growth factor receptor tyro-
sine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism
of action. J Cell Physiol 2003, 194:13–19.
This is an interesting review of the molecular mechanisms of action of small-
molecule EGFR TKIs.
13 Ciardiello F, Caputo R, Bianco R, et al.: Antitumor effect and potentiation of
cytotoxic drug activity in human cancer cells by ZD-1839 (Iressa), an epider-
mal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer
Res 2000, 6:2053–2063.
14 Sirotnak FM, Zakowsky MF, Miller VA, et al.: Efficacy of cytotoxic agents
against human tumor xenografts is markedly enhanced by coadministration of
ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res
2000, 6:4885–4892.
15 Wakeling A, Guy SP, Woodburn JR, et al.: ZD1839 (Iressa): an orally active
inhibitor of epidermal growth factor receptor signaling with potential for can-
cer therapy. Cancer Res 2002, 62:5749–5754.
••
16 Ranson M, Hammond LA, Ferry D, et al.: ZD1839, a selective oral epidermal
growth factor receptor–tyrosine kinase inhibitor, is well tolerated and active in
patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol
2002, 20:2240–2250.
This is one of the phase 1 studies with gefitinib, showing activity in NSCLC pa-
tients.
••
17 Herbst RS, Maddox A-M, Rothenberg ML, et al.: Selective oral epidermal
growth factor receptor tyrosine inhibitor ZD1839 is generally well-tolerated
and has activity in non-small-cell lung cancer and other solid tumors: results of
a phase I trial. J Clin Oncol 2002, 20:3815–3828.
This is one of the phase 1 studies with gefitinib, showing activity in NSCLC pa-
tients.
18 Baselga J, Rischin D, Ranson M, et al.: Phase I safety, pharmacokinetic, and
pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor
receptor tyrosine kinase inhibitor, in patients with five selected tumor types.
J Clin Oncol 2002, 21:4292–4302.
19 Nakagawa K, Tamura T, Negoro S, et al.: Phase I pharmacokinetic trial of the
selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefi-
tinib (“Iressa”, ZD1839) in Japanese patients with solid malignant tumors.
Ann Oncol 2003, 14:922–930.
•
20 LoRusso P, Herbst RS, Rischin D, et al.: Improvements in quality of life and
disease-related symptoms in phase I trials of the selective oral epidermal
growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung
cancer and other solid tumors. Clin Cancer Res 2003, 9:2040–2048.
This article assesses the quality of life in patients receiving gefitinib during the
phase 1 program.
••
21 Fukuoka M, Yano S, Giaccone G, et al.: Multi-institutional randomized phase
II trial of gefitinib for previously treated patients with advanced non-small-cell
lung cancer. J Clin Oncol 2003, 22:2237–2246.
134 Lung and mediastinum
This paper presents the results of the IDEAL 1 trial in second- and third-line treat-
ment of advanced NSCLC patients.
••
22 Kris MG, Natale RB, Herbst RS, et al.: Efficacy of gefitinib, an inhibitor of the
epidermal growth factor receptor tyrosine, in symptomatic patients with non-
small cell lung cancer. JAMA 2003, 290:2149–2158.
This paper presents the results of the IDEAL 2 trial in third- and fourth-line treatment
of symptomatic, advanced NSCLC patients.
23 Cohen MH, Williams GA, Sridhara R, et al.: FDA approval summary: gefitinib
(ZD1839) (Iressa) tablets. Oncologist 2003, 8:303–306.
24 Cappuzzo F, Gregorc V, Rossi E, et al.: Gefitinib in pretreated non-small-cell
lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and
epidermal growth factor receptor expression in locally advanced or metastatic
NSCLC. J Clin Oncol 2003, 21:2658–2663.
25 Pallis AG, Mavroudis D, Androulakis N, et al.: ZD1839, a novel, oral epidermal
growth factor receptor–tyrosine kinase inhibitor, as salvage treatment in pa-
tients with advanced non-small cell lung cancer. Experience from a single
center participating in a compassionate use program. Lung Cancer 2003,
40:301–307.
•
26 Gridelli C, Maione P, Castaldo V, et al.: Gefitinib in elderly and unfit patients
affected by advanced non-small-cell lung cancer. Br J Cancer 2003,
89:1827–1829.
This report demonstrates gefitinib activity in elderly and unfit patients.
27 Takao M, Inoue K, Watanabe F, et al.: Successful treatment of persistent
bronchorrhea by gefitinib in a case with recurrent bronchioloalveolar carci-
noma: a case report. World J Surg Oncol 2003, 8:1–3.
28 Gelibter A, Ceribelli A, Milella M, et al.: Clinically meaningful response to the
EGFR tyrosine kinase inhibitor gefitinib (“Iressa,” ZD1839) in non small cell
lung cancer. J Exp Clin Cancer Res 2003, 22:481–485.
29 Fuijwara K, Kiura K, Ueoka H, et al.: Dramatic effect of ZD1839 (“Iressa”) in a
patient with advanced non-small-cell lung cancer and poor performance sta-
tus. Lung Cancer 2003, 40:73–76.
•
30 Villano JL, Mauer AM, Vokes EE: A case study documenting the anticancer
activity of ZD1839 (Iressa) in the brain. Ann Oncol 2003, 14:656–657.
This is the first case report of gefitinib activity on brain metastasis in a patient with
NSCLC.
•
31 Cappuzzo F, Ardizzoni A, Soto–Parra H, et al.: Epidermal growth factor re-
ceptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases
from non-small cell lung cancer. Lung Cancer 2003, 41:227–231.
This article presents a series of NSCLC patients with brain metastasis responding
to gefitinib monotherapy.
•
32 Wu YL, Yang X-N, Gu L-J: The characteristics of patients with non-small cell
lung cancer with complete response treated with ZD1839 [abstract no.
2770]. Proc Am Soc Clin Oncol 2003, 22:689.
This paper presents evidence of gefitinib activity in select NSCLC patients (those
with adenocarcinoma and bronchioloalveolar histology).
•
33 Wong N-S, Lim ST, Lim W-T, et al.: ZD1839 is more effective in patients with
non-small cell lung cancer (NSCLC) who were lifetime non-tobacco users
[abstract no. 2790]. Proc Am Soc Clin Oncol 2003, 22:694.
This paper presents evidence of gefitinib activity in select NSCLC patients (non-
smokers).
•
34 Shah NT, Miller VA, Kris MG, et al.: Bronchioalveolar histology and smoking
history predict response to gefitinib [abstract no. 2524]. Proc Am Soc Clin
Oncol 2003, 22:628.
This paper presents evidence of gefitinib activity in select NSCLC patients (adeno-
carcinoma and bronchioloalveolar histology and in nonsmokers).
35 Miller VA, Johnson D, Krug LM, et al.: A pilot trial of the epidermal growth
factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and pacli-
taxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol
2003, 21:2094–2100.
36 Manegold C, Gatzemeier U, Smith R, et al.: Final data from a pilot trial of
gefitinib (“Iressa,” ZD1839) in combination with docetaxel in patients with
advanced or metastatic non-small-cell lung cancer: safety and pharmacoki-
netics [abstract no. 2635]. Proc Am Soc Clin Oncol 2003, 22:655.
37 Rixe O, Lemarie E, Chomy F, et al.: Phase II combination of gefitinib (“Iressa,”
ZD1839) and docetaxel for non-small-cell lung cancer: clinical results and
biological monitoring [abstract no. 2659]. Proc Am Soc Clin Oncol 2003,
22:661.
•
38 Giaccone G, Johnson DH, Manegold C, et al.: A phase III clinical trial of
ZD1839 (“Iressa”) in combination with gemcitabine and cisplatin in chemo-
therapy-naive patients with advanced non-small-cell lung cancer (INTACT 1)
[abstract no. 4]. Ann Oncol 2002, 13:2.
This is the first report from the INTACT 1 trial of gefitinib in combination with che-
motherapy as first-line therapy in advanced NSCLC.
•
39 Johnson DH, Herbst R, Giaccone G, et al.: ZD1839 (“Iressa”) in combination
with paclitaxel and carboplatin in chemotherapy-naive patients with advanced
non-small-cell lung cancer (NSCLC): results from a phase III clinical trial
(INTACT 2) [abstract no. 468]. Ann Oncol 2002, 13:127.
This is the first report from the INTACT 2 trial of gefitinib in combination with che-
motherapy as first-line therapy in advanced NSCLC.
40 Sridhar SS, Seymour L, Shepherd FA: Inhibitors of epidermal-growth-factor
receptors: a review of clinical research with a focus on non-small-cell lung
cancer. Lancet Oncol 2003, 4:397–406.
••
41 Dancey JE, Freidin B: Targeting epidermal growth factor receptor—are we
missing the mark? Lancet 2003, 362:62–64.
This is an interesting review of the open clinical issues of how to perform clinical
trials with EGFR inhibitors.
•
42 Inoue A, Saijo Y, Maemondo M, et al.: Severe interstitial pneumonia and ge-
fitinib. Lancet 2003, 361:137–139.
This is the first Japanese report on ILD and gefitinib in NSCLC.
•
43 Soria J-C, Le Chevalier T: Interstitial lung disease in NSCLC. Signal 2003,
4:2–3.
This is an extensive review of ILD in NSCLC patients treated with different thera-
pies, including chemotherapy and ionizing radiation.
44 Hidalgo M, Siu LL, Nemunaitis J, et al.: Phase I and pharmacologic study of
OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in
patients with advanced solid malignancies. J Clin Oncol 2001, 19:3267–
3279.
45 Perez–Soler R, Chachoua A, Huberman M, et al.: A phase II trial of the epi-
dermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, fol-
lowing platinum-based chemotherapy, in patients (pts) with advanced,
EGFR-expressing, non-small cell lung cancer (NSCLC) [abstract no. 1235].
Proc Am Soc Clin Oncol 2001, 20:301a.
••
46 Clark GM, Perez–Soler R, Siu L, et al.: Rash severity is predictive of increased
survival with erlotinib HCl [abstract no. 786]. Proc Am Soc Clin Oncol 2003,
22:196.
This is an intriguing observation of the correlation between skin rash and outcome
in NSCLC patients treated with erlotinib.
47 Herbst RS: Erlotinib (Tarceva): an update on the clinical trial program. Semin
Oncol 2003, 30:34–46.
48 Mendelsohn J: Blockade of receptors for growth factors: an anticancer
therapy. Clin Cancer Res 2000, 6:747–753.
49 Baselga J, Pfister D, Cooper MR, et al.: Phase I studies of anti-epidermal
growth factor receptor chimeric antibody C225 alone and in combination
with cisplatin. J Clin Oncol 2000, 18:904–914.
50 Robert F, Blumenschein G, Dicke K, et al.: Phase IB/IIA study of anti-
epidermal growth factor receptor antibody, cetuximab, in combination with
gemcitabine/carboplatin in patients with advanced stage IV non-small cell
lung cancer [abstract no. 2587]. Proc Am Soc Clin Oncol 2003, 23:643.
51 Kelly K, Hanna N, Rosenberg A, et al.: A multicenter phase I/II study of cetux-
imab in combination with paclitaxel and carboplatin in untreated patients with
stage IV non-small cell lung cancer [abstract no. 2592]. Proc Am Soc Clin
Oncol 2003, 23:644.
52 Kim ES, Mauer AM, Tran HT, et al.: A phase II study of cetuximab, an IgG1
epidermal growth factor receptor-blocking antibody, in combination with
docetaxel in chemotherapy-refractory/resistant patients with advanced non-
small cell lung cancer: final report [abstract no. 2581]. Proc Am Soc Clin
Oncol 2003, 23:642.
••
53 Gatzemeier U, Rosell R, Ramlau R, et al.: Cetuximab (C225) in combination
with cisplatin/vinorelbine vs cisplatin/vinorelbine alone in the first-line treat-
ment of patients (pts) with epidermal growth factor receptor (EGFR) positive
advanced non-small-cell lung cancer (NSCLC) [abstract no. 2582]. Proc Am
Soc Clin Oncol. 2003, 23:642.
This is the first clinical evidence of the activity of the combination of doublet che-
motherapy plus cetuximab as first-line therapy in EGFR-positive NSCLC patients in
a randomized phase 2 study.
••
54 Ciardiello F, Tortora G: Epidermal growth factor receptor (EGFR) as a target
in cancer therapy: understanding the role of receptor expression and other
molecular determinants that could influence the response to anti-EGFR
drugs. Eur J Cancer 2003, 39:1348–1354.
This is an extensive review of the known factors and of the potential mechanisms
that could influence patient response to EGFR inhibitors.
EGFR inhibitors in NSCLC Ciardiello et al. 135
